<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964496</url>
  </required_header>
  <id_info>
    <org_study_id>rjyyxhk3015</org_study_id>
    <nct_id>NCT00964496</nct_id>
  </id_info>
  <brief_title>Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation</brief_title>
  <official_title>Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Repeated episodes of bleeding from gastrointestinal vascular malformations
      refractory to endoscopic or surgical therapy often pose a major therapeutic challenge.

      Methods: The investigators performed a randomized, parallel controlled study of thalidomide
      as a therapy for recurrent gastrointestinal bleeding due to vascular malformation. Patients
      with at least six episodes of bleeding in the prior year due to vascular malformation were
      randomly grouped, prescribed a four-month regimen of either 25 mg of thalidomide or 100 mg of
      iron orally four times daily, and monitored for at least one year. The primary end point was
      defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months and the
      cessation of bleeding. Rebleeding was defined based on a positive fecal occult blood test
      (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. Secondary
      outcomes included the participants dependent on blood transfusions and changes from baseline
      in transfused packed red cell units, bleeding episodes, bleeding durations, and hemoglobin
      levels at 12 months. Statistical significance was defined at P &lt; 0.05.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Description:

      This is an exploratory, randomized, parallel controlled study of thalidomide for recurrent
      gastrointestinal bleeding from vascular malformations. Informed consent was taken from all
      subjects and the Institute Ethics Committee approved the study protocol. All procedures were
      in accordance with the Declaration of Helsinki. The study was supported by no pharmaceutical
      funding.

      Study design and Intervention:

      From Nov. 2004 to Nov. 2007, patients with repeated episodes of chronic gastro-intestinal
      bleeding due to vascular malformations identified by oesophagogastroduodenoscopy, capsule
      endoscope or double-balloon endoscope were enrolled (according our enrollment criteria).

      The patients were randomly assigned to receive a four-month course of either 25 mg of
      thalidomide or 100mg iron orally at daily time 6 a.m.,12 noon,6 p.m. and 10 p.m.,
      respectively.

      Randomization was performed through the proc plan procedure of Statistical Analysis Software
      (SAS), using the method of randomly permuted blocks of 4. Within each block, the number of
      patients allocated to each of the two treatments was equal. Each patient who met the
      inclusion criteria was consecutively assigned a random number in chronological order, which
      allocated him or her to one of the treatment groups. A blinded research nurse supervised
      patient randomization and drug administration.

      In the case of an adverse event, the study medication was temporarily or permanently
      discontinued based on subject inclination and toxicity intolerance. Concomitant therapies,
      such as blood transfusions and other symptomatic treatments like iron supplementation, were
      performed in both groups as necessary during the four-month treatment and subsequent
      follow-up periods. Blood transfusion was indicated and recorded when the hemoglobin (Hb)
      level reached &lt; 7.0 g/dl. Red-cell transfusions were administered according to patient Hb
      level as follows: 2 units were administered for 6.1 g/dl ≥ Hb ≤ 7.0 g/dl, 3 units for 5.1
      g/dl ≥ Hb ≤ 6.0 g/dl, and 4 units for Hb &lt; 5.0 g/dl. Iron was provided for patients with 7.0
      g/dl ≥ Hb ≤ 11.0 g/dl. After the four-month treatment course, all patients discontinued study
      medications except for cases where symptomatic treatments were necessary as described above.

      Assessment of response and adverse events:

      The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥
      50% at 12 months and the cessation of bleeding. Rebleeding was defined based on a positive
      fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit
      after treatment. Secondary outcomes included the participants dependent on blood transfusions
      and changes from baseline in transfused packed red cell units, bleeding episodes, bleeding
      durations, and hemoglobin levels at 12 months.

      Adverse events included any unfavorable change in health, including abnormal laboratory
      findings, during the study or follow-up period.

      Evaluation of Patients and Follow-up:

        -  Certified research nurses collected information on the demographics and medical and
           social histories of all patients enrolled in the study.

        -  After screening and baseline evaluations, the patients were closely monitored in the
           hospital for at least one week. They were then followed twice monthly during the
           four-mouth course of treatment and once a month thereafter.

        -  Clinical follow-up was performed by qualified doctors. At all visits, the
           bleeding-related parameters (number and duration), a physical examination was performed
           and laboratory values were obtained for FOBT, complete blood counts, serum chemistries,
           and hepatic and renal function. Neuropathy and other adverse events were also assessed.

        -  Patients were advised to refrain from any other non-prescribed medicines, especially
           rebleeding-related medications such as aspirin, nonsteroidal antiinflammatory drugs
           (NSAIDs), anti-platelet drugs, anticoagulants, and Chinese medications (with
           salicylates), gingko, or Echinacea.

      Measurement of Vascular Endothelial Growth Factor (VEGF) in Sera:

      Laboratory assays for VEGF were performed at baseline and after the four-month treatment
      course in the thalidomide group, by a technician blinded to the assignment and final
      assessment. Three milliliters of serum of peripheral venous blood samples were centrifuged
      (3000 r/min at 4°C, 10 min), extracted, separated into freezing tubes, and stored at -70°C
      for no more than 4 months. Plasma VEGF levels (in pg/ml) were determined in duplicate using
      sandwich ELISA kits (R&amp;D Systems, USA) in a laboratory of the Shanghai Research Institute of
      Digestive Disease. Samples from each patient were batch-tested in a single run. For quality
      control, all samples were retested two more times in a subsequent run to confirm the results
      of the first run.

      Statistical Analysis:

      To our knowledge, no similar such study has previously been performed, and we were thus
      unable to refer to published studies to determine our samples. To this end, we performed an
      unpublished preliminary study. Response in the iron-control group and thalidomide group
      reached 10% and 80%, due to loose inclusion criteria (bleeding history was not restricted).
      For this study, we estimated that the primary outcome (the proportion of subjects whose
      number of yearly bleeds had decreased by ≥ 50%) would occur in 10% of the control group and
      80% of the thalidomide group patients. An equally divided sample of 11 subjects was deemed
      sufficient for detecting the primary end point, with a type I error (two-sided) of 5% and a
      power of 90%. Assuming a 10% volunteer attrition rate to follow-up, we established a target
      sample size of 13 per group (calculated with nquery advisor software 5.0).

      Analyses of the responses and adverse events were performed on all registered patients
      according to the intention-to-treat principle. Statistical analysis was performed by a
      blinded biostatistician with the Statistical Product and Service Solutions (SPSS) 13.0
      software package. We simultaneously analyzed the primary endpoint of the full analysis set
      (FAS) and per protocol set (PPS). Continuous variables were compared using a two-sample
      independent t-test or Wilcoxon rank-sum test. Categorical variables were compared using the
      chi-squared and Fisher's exact tests. A paired t-test was employed to compare differences in
      plasma VEGF levels before and after thalidomide treatment. The Breslow-Day test was used to
      test for the heterogeneity of treatment effects across strata. All reported P-values are
      two-sided. Data are reported as the mean ± standard deviation (SD) or median (range) for
      continuous variables and number (%) for categorical variables. Since adjustments to the
      control group were minimal, we also reported point estimates and 95% confidence intervals
      (CIs). For all outcomes, a P-value of &lt; 0.05 was considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cessation of Bleeding</measure>
    <time_frame>52 months</time_frame>
    <description>The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin (Hb) Level at 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bleeding Episodes at 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The Change from baseline in bleeding episodes at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bleeding Duration at 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The change from baseline in bleeding duration at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Dependent on Blood Transfusions</measure>
    <time_frame>52 months</time_frame>
    <description>Numbers of participants dependent on blood transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Transfused Red Cell Requirements at 12 Months</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Obscure Gastrointestinal Bleeding</condition>
  <condition>Angiodysplasia</condition>
  <condition>Gastric Antral Vascular Ectasia</condition>
  <condition>Thalidomide</condition>
  <arm_group>
    <arm_group_label>Thalidomide Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron-controlled Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.</description>
    <arm_group_label>Thalidomide Group</arm_group_label>
    <other_name>Softenon;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron</intervention_name>
    <description>Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.</description>
    <arm_group_label>Iron-controlled Group</arm_group_label>
    <other_name>Ferrous Succinate Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 40-85 years; women were post-menopausal, post-tubal ligation, or on some
             form of birth control like long-term laying up contraceptive ring or using condom;

          -  History of at least six documented gastrointestinal bleeding episodes in the year
             prior to randomization, which were refractory or inaccessible to endoscopic therapy or
             surgical ectomy;

          -  Confirmed diagnosis of vascular malformation by esophagogastroduodenoscopy (EGD),
             capsule endoscope (CE), double-balloon endoscope (DBE), or colonoscopy, but no obvious
             infectious, neoplastic, or other specific diagnosis;

          -  Angiodysplasia at endoscopy characterized by focal or diffused venous/capillary
             lesions presenting as bright red ectatic vessels or pulsatile red protrusions, with
             surrounding venous dilatation or patchy erythema with or without oozing;

          -  Endoscopic appearance of GAVE (also known as watermelon stomach), indicated by
             longitudinal antral folds converging on the pylorus, containing visible columns of
             tortuous red ecstatic vessels.

        Exclusion Criteria:

          -  Patients were excluded if their bleeding history were less than 1 year;

          -  if they had cirrhotic or portal hypertension gastropathy; severe co-morbidities of
             cardiac, pulmonary, renal, liver, hematological, rheumatologic disorders, or
             uncontrollable diabetes mellitus or hypertension;

          -  if they had a history of severe bilateral peripheral neuropathy or seizure activity,
             thromboembolic disease, known thalidomide or iron allergy, or prior treatment of
             gastrointestinal bleeding with thalidomide;

          -  if they had a history of treatment with any dose of systemic or oral topical
             corticosteroids or aspirin, NSAIDs, anti-platelet drugs, anticoagulants, or Chinese
             medications (with salicylates), gingko, or Echinacea, or other putative
             immunomodulators or anti-angiogenic agents;

          -  Currently pregnant or lactating or currently undergoing systemic cancer chemotherapy
             or receiving radiation

          -  if they were undergoing systemic cancer chemotherapy or receiving radiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhizheng Ge, MD. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Ren Ji Hospital</affiliation>
  </overall_official>
  <link>
    <url>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=THALOMID&amp;CFID=21312735&amp;CFTOKEN=394df9d228870faa-4F4FD0A6-1372-5AE1-6AD225831B3F092E</url>
    <description>Approved drug page at FDA's Drugs@FDA web site.</description>
  </link>
  <link>
    <url>http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=25&amp;tableName=TABLE25&amp;title</url>
    <description>Ferrous Succinate Tablets. Approved drug page at China Food and Drug Administration's web site</description>
  </link>
  <reference>
    <citation>Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 May 22;336(21):1487-93.</citation>
    <PMID>9154767</PMID>
  </reference>
  <reference>
    <citation>Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut. 2004 Apr;53(4):609-12.</citation>
    <PMID>15016759</PMID>
  </reference>
  <reference>
    <citation>Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol. 2003 Jan;98(1):221-2.</citation>
    <PMID>12526972</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <results_first_submitted>August 26, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2010</results_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <name_title>Zhizheng Ge, MD. Ph.D ,Professor ,Shanghai Ren Ji Hospital</name_title>
    <organization>Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine</organization>
  </responsible_party>
  <keyword>vascular malformation</keyword>
  <keyword>gastrointestinal bleeding</keyword>
  <keyword>thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Angiodysplasia</mesh_term>
    <mesh_term>Gastric Antral Vascular Ectasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From November 2004 to November 2007, a total of 59 subjects were assessed for eligibility at Shanghai Ren Ji Hospital, China.</recruitment_details>
      <pre_assignment_details>Among the 59 patients, two refused to enter the protocol and two other were excluded owing to severe associated disease with short life expectancy. Therefore, 55 patients were enrolled in our study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Thalidomide Group</title>
          <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
        <group group_id="P2">
          <title>Iron-controlled Group</title>
          <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thalidomide Group</title>
          <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
        <group group_id="B2">
          <title>Iron-controlled Group</title>
          <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Outcome</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Completion of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incomplete study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transfusion dependence</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>dependent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>independent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ways of diagnose</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Capsule endoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enteroscopies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Activated partial thromboplastin time (APTT)</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4929" spread="6.4430"/>
                    <measurement group_id="B2" value="28.0667" spread="5.9947"/>
                    <measurement group_id="B3" value="27.7745" spread="6.1760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follow-up time</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9286" spread="13.73810"/>
                    <measurement group_id="B2" value="36.1481" spread="13.49274"/>
                    <measurement group_id="B3" value="35.5273" spread="13.50563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glutamic-pyruvic transaminase (GPT)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8143" spread="13.4963"/>
                    <measurement group_id="B2" value="25.2019" spread="14.1123"/>
                    <measurement group_id="B3" value="25.0045" spread="12.4753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of bleeding time</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="4.1404" lower_limit="1" upper_limit="21"/>
                    <measurement group_id="B2" value="3" spread="4.4331" lower_limit="1" upper_limit="20"/>
                    <measurement group_id="B3" value="5" spread="4.2552" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean corpuscular volume (MCV)</title>
          <units>femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.8000" spread="3.9711"/>
                    <measurement group_id="B2" value="75.2444" spread="4.4130"/>
                    <measurement group_id="B3" value="76.0364" spread="4.2282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Corpuscular Hemoglobin Concentration</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295.8571" spread="15.2624"/>
                    <measurement group_id="B2" value="299.0000" spread="13.3012"/>
                    <measurement group_id="B3" value="297.4000" spread="14.2888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count (PLT)</title>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="206.4536" spread="53.1686"/>
                    <measurement group_id="B2" value="197.7111" spread="60.0851"/>
                    <measurement group_id="B3" value="202.1618" spread="56.3131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre- packed red cell units transfused per year</title>
          <description>Total packed red cell units transfused per year(milliliter) before randomization in transfusion dependent subjects.</description>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1928.57" spread="763.02"/>
                    <measurement group_id="B2" value="1985.71" spread="766.47"/>
                    <measurement group_id="B3" value="1957.14" spread="751.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bleeding duration</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.8214" spread="3.0799" lower_limit="5" upper_limit="20"/>
                    <measurement group_id="B2" value="8.7407" spread="4.5029" lower_limit="3" upper_limit="21"/>
                    <measurement group_id="B3" value="8.7818" spread="3.8088" lower_limit="3" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-treatment hemoglobin level</title>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4000" spread="1.7904"/>
                    <measurement group_id="B2" value="5.9919" spread="1.5304"/>
                    <measurement group_id="B3" value="6.1996" spread="1.6652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prothrombin time-international normalized ratio (PT-INR)</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0550" spread="0.1530"/>
                    <measurement group_id="B2" value="1.0989" spread="0.1533"/>
                    <measurement group_id="B3" value="1.0765" spread="0.1534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.5536" spread="20.9532"/>
                    <measurement group_id="B2" value="88.9296" spread="24.2665"/>
                    <measurement group_id="B3" value="83.1382" spread="23.1514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total bilirubin</title>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1607" spread="4.4212"/>
                    <measurement group_id="B2" value="9.1407" spread="4.1196"/>
                    <measurement group_id="B3" value="9.1509" spread="4.2361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White blood cell (WBC)</title>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4429" spread="1.5704"/>
                    <measurement group_id="B2" value="6.5926" spread="1.7389"/>
                    <measurement group_id="B3" value="6.5164" spread="1.6416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>pre-bleeding episodes per year</title>
          <units>bleeding episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.96" spread="3.383" lower_limit="7" upper_limit="19"/>
                    <measurement group_id="B2" value="13.96" spread="3.469" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="B3" value="13.96" spread="3.394" lower_limit="7" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months</title>
        <description>The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months</title>
          <description>The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the participants whose rebleeds decreased from baseline by ≥ 50% at 12 months.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the participants whose rebleeds decreased from baseline by ≥ 50% at 12 months.
Comparisons were performed with the use of the chi-square test, Fisher’s exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00000013</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Differences in proportions</param_type>
            <param_value>0.677</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.547</ci_lower_limit>
            <ci_upper_limit>0.807</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin (Hb) Level at 12 Months</title>
        <description>The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin (Hb) Level at 12 Months</title>
          <description>The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months.</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="2.08"/>
                    <measurement group_id="O2" value="-0.01" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the change from baseline in hemoglobin level at 12 months.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the change from baseline in hemoglobin level at 12 months.
Comparisons were performed with the use of the independent-samples t test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.02</ci_lower_limit>
            <ci_upper_limit>-2.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bleeding Episodes at 12 Months</title>
        <description>The Change from baseline in bleeding episodes at 12 months</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bleeding Episodes at 12 Months</title>
          <description>The Change from baseline in bleeding episodes at 12 months</description>
          <units>bleeding episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.36" spread="4.31"/>
                    <measurement group_id="O2" value="1.41" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the change from baseline in bleeding episodes at 12 months.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the change from baseline in bleeding episodes at 12 months.
Comparisons were performed with the use of the independent-samples t test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.00</ci_lower_limit>
            <ci_upper_limit>9.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bleeding Duration at 12 Months</title>
        <description>The change from baseline in bleeding duration at 12 months</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bleeding Duration at 12 Months</title>
          <description>The change from baseline in bleeding duration at 12 months</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.0"/>
                    <measurement group_id="O2" value="0.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the change from baseline in bleeding duration at 12 months.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the change from baseline in bleeding duration at 12 months.
Comparisons were performed with the use of the independent-samples t test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00024740</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.15</ci_lower_limit>
            <ci_upper_limit>6.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Dependent on Blood Transfusions</title>
        <description>Numbers of participants dependent on blood transfusions</description>
        <time_frame>52 months</time_frame>
        <population>55 patients were enrolled in our study. One in iron-controlled group refused to continue for personal reason after 8 months, two other in thalidomide plus iron group refused to take study medications after 4 weeks treatment due to leukopenia and unexplained somnolence. Analysis was performed according to Intention-to-Treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Dependent on Blood Transfusions</title>
          <description>Numbers of participants dependent on blood transfusions</description>
          <population>55 patients were enrolled in our study. One in iron-controlled group refused to continue for personal reason after 8 months, two other in thalidomide plus iron group refused to take study medications after 4 weeks treatment due to leukopenia and unexplained somnolence. Analysis was performed according to Intention-to-Treat principle.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the participants dependent on blood transfusions.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the participants dependent on blood transfusions.
Comparisons were performed with the use of the chi-square test, Fisher’s exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00298881</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Differences in proportions</param_type>
            <param_value>-0.374</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.563</ci_lower_limit>
            <ci_upper_limit>-0.185</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Transfused Red Cell Requirements at 12 Months</title>
        <description>Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>There are 14 participants depended on blood transfusion in each group</population>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Transfused Red Cell Requirements at 12 Months</title>
          <description>Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients</description>
          <population>There are 14 participants depended on blood transfusion in each group</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1585.71" spread="446.97"/>
                    <measurement group_id="O2" value="-28.57" spread="106.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the change from baseline in total transfused red cell requirements at 12 months.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the change from baseline in total transfused red cell requirements at 12 months.
Comparisons were performed with the use of the independent-samples t test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>P&lt;0.05 was considered as statistical different, while P&gt;0.05 was considered as no statistical significance between two groups. All reported P values are two-sided.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1557.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1294.53</ci_lower_limit>
            <ci_upper_limit>1819.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cessation of Bleeding</title>
        <description>The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment.</description>
        <time_frame>52 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thalidomide Group</title>
            <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
          <group group_id="O2">
            <title>Iron-controlled Group</title>
            <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
          </group>
        </group_list>
        <measure>
          <title>Cessation of Bleeding</title>
          <description>The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis (H0): Thalidomide 100 mg per day is equivalence to iron 400 mg per day with regard to the cessation of bleeding.
Alternative hypothesis (Ha): Thalidomide 100 mg per day is non-equivalent to iron 400 mg per day with regard to the cessation of bleeding.
Comparisons were performed with the use of the chi-square test, Fisher’s exact test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00003962</p_value>
            <method>Fisher Exact</method>
            <param_type>Differences in proportions</param_type>
            <param_value>0.464</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during 4-month treatment and thereafter medium 39 months (range: 8 to 52 months) of follow-up.</time_frame>
      <desc>Adverse events were considered if any uncomfortable symptoms occur and relevant to our study medications. Severe adverse events (SAE’s) were considered if the complained symptoms resulted in more hospitalization or that threaten the patients lives.</desc>
      <group_list>
        <group group_id="E1">
          <title>Thalidomide Group</title>
          <description>interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
        <group group_id="E2">
          <title>Iron-controlled Group</title>
          <description>interventions administered (dosage, 400mg; dosage form, 100mg; frequency of administration, 4 times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in vaginal discharge</sub_title>
                <counts group_id="E1" events="60" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dryness of eye</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="12" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bitter taste</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="92" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="18" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nuasea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="18" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="82" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="72" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Shingles zoster Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hands tremble</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Numb limb</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single center, open-label study; lack of placebo pills, make it impossible on equality of dosages between two groups; lack of dose response assessment either in patients or assays of serum vascular endothelial growth factor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zhizheng Ge, MD. Ph.D. Director of the Clinical Trials</name_or_title>
      <organization>Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine</organization>
      <phone>86-21-68383015</phone>
      <email>zhizhengge@yahoo.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

